Figure 3 | Scientific Reports

Figure 3

From: Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4

Figure 3

Dose-response characterization of the influence of thalidomide, lenalidomide, pomalidomide, atRA, and SB431542 on LPM differentiation in Gibco hiPSCs. High content imaging analysis of Gibco hiPSCs that were differentiated for 2 days in APEL2 + GSKi in the presence of compound and subsequently stained for FOXF1 and NANOG (only FOXF1 data shown here) and counter-stained with DAPI. Untreated DMSO control is represented as the lowest concentration in in each graph. (A,B) Data represent the mean +/− SEM %FOXF1 +/DAPI+ cells from at least 4 independent experiments. Nonlinear regression analysis was performed using the 4-parameter [inhibitor] vs response variable slope plotting tool in GraphPad Prism. (A) Dose-response of thalidomide (black), lenalidomide (blue), and pomalidomide (red). (B) Dose-response of atRA (filled circles) and SB431542 (hollow circles).

Back to article page